Acorda Therapeutics Announces FDA Approval of AMPYRA™ (dalfampridine) to Improve Walking in People with Multiple Sclerosis –

Acorda Therapeutics Announces FDA Approval of
AMPYRA™ (dalfampridine)

to Improve Walking in People with Multiple Sclerosis – Demonstrated by Increases in Walking Speed

· First and Only FDA-Approved Therapy Addressing Walking Impairment

· AMPYRA Previously Referred to as Fampridine-SR

· AMPYRA Expected to be Available by Prescription in March 2010

· Acorda Conference Call Today at 5:30 p.m. Eastern Time



HAWTHORNE, N.Y., January 22, 2010 – Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has received marketing approval from the U.S. Food and Drug Administration (FDA) for AMPYRA™ (dalfampridine), an oral treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed. AMPYRA demonstrated efficacy in people with all four major types of MS (relapsing remitting, secondary progressive, progressive relapsing and primary progressive). AMPYRA can be used alone or with existing MS therapies, including immunomodulator drugs.



“The approval of AMPYRA marks an important milestone for the many people with MS who suffer walking impairment. Difficulty walking is often cited by those with MS as one of the most pervasive and challenging aspects of their disease,” said Ron Cohen, M.D., President and CEO of Acorda Therapeutics, adding “We are enormously gratified to have achieved approval for the only medication indicated to improve walking in people with MS, and we thank all of the clinicians, people living with MS and medical and patient support organizations who joined in this effort over the past decade. Reaching this milestone underscores Acorda’s ongoing commitment to develop innovative therapies for people with neurological diseases.”

» Read More

Please return to this page to leave comments. Thank You

######################

.
Keep Informed with News and Information regarding Multiple Sclerosis. If not yet receiving the "Stu's Views and MS Related News", weekly M.S. e-newsletter, then please take 20 seconds to register at: http://www.msviewsandnews.org . - Thank you
.

============================================